Search | Clinical Trials Finder

Conditions: Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma, Ewing Sarcoma, Wilms Tumor, Adrenocortical Cancer, Desmoplastic Small Round Cell Tumor, Germ Cell Cancer, Rhabdoid Tumor, Clear Cell Sarcoma, Hepatoblastoma, Melanoma, Carcinoma, Malignant Peripheral Nerve Sheath Tumors, Soft Tissue Sarcoma
Interventions: Fludarabine, Cyclophosphamide, MESNA, B7-H3 CAR T cells; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Premature Birth, Premature Infant, Premature, Intrauterine Growth Restriction, Small for Gestational Age at Delivery
Interventions: PEAPOD Infant Body Composition measuring device; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 22 Weeks to 32 Weeks
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Prognathism, Retrognathism, Dentofacial Deformities
Interventions: Not listed
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 2 Years to 100 Years
Enrollment: 2,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2046
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Autosomal Dominant Hypocalcemia
Interventions: Not listed
Lead sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company; Industry
Eligibility: Up to 90 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 9
States / cities: Oakland, California • Aurora, Colorado • Jacksonville, Florida + 6 more

Conditions: Stroke (CVA) or TIA, Diabetes, Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease), Sepsis, Hypertension, Heart Failure, Pneumonia, Urinary Tract Infection (Diagnosis), Chest Pain, Psychiatric Disorder, Sickle Cell Disease (SCD)
Interventions: Not listed
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 30,486 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Vulvar Lichen Sclerosus
Interventions: The CO2RE® System; Device
Lead sponsor: Candela Corporation; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Jacksonville, Florida • Cincinnati, Ohio • South Burlington, Vermont

Conditions: Fetal Alcohol Spectrum Disorders, Attention Deficit Hyperactivity Disorder
Interventions: Trigeminal Nerve Stimulation (TNS); Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 8 Years to 12 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 20 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome, Maroteaux Lamy Syndrome, Sly Syndrome, Alpha-Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Glycoprotein Metabolic Disorders, Sphingolipidoses, Recessive Leukodystrophies, Globoid Cell Leukodystrophy, Metachromatic Leukodystrophy, Niemann-Pick B, Niemann-Pick C Subtype 2, Sphingomyelin Deficiency, Peroxisomal Disorders, Adrenoleukodystrophy With Cerebral Involvement, Zellweger Syndrome, Neonatal Adrenoleukodystrophy, Infantile Refsum Disease, Acyl-CoA Oxidase Deficiency, D-Bifunctional Enzyme Deficiency, Multifunctional Enzyme Deficiency, Alpha-methylacyl-CoA Racmase Deficiency, Mitochondrial Neurogastrointestingal Encephalopathy, Severe Osteopetrosis, Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation), Inherited Metabolic Disorders
Interventions: Stem Cell Transplantation, IMD Preparative Regimen, Osteopetrosis Only Preparative Regimen, Osteopetrosis Haploidentical Only Preparative Regimen, cALD SR-A (Standard-Risk, Regimen A), cALD SR-B (Standard-Risk, Regimen B), cALD HR-D (High-Risk, Regimen C), cALD HR-D (High-Risk, Regimen D); Biological · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 55 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2029
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Kidney Cancer, Leukemia, Lymphoma, Neurotoxicity, Peripheral Neuropathy, Sarcoma
Interventions: glutamic acid, placebo; Drug · Other
Lead sponsor: University of South Florida; Other
Eligibility: 3 Years to 20 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 6
States / cities: Fort Myers, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 3 more

Conditions: Fetal Alcohol Spectrum Disorders
Interventions: Choline Bitartrate; Drug
Lead sponsor: Jeff Wozniak; Other
Eligibility: 30 Months to 72 Months
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Solid Tumors
Interventions: RMC-5552; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Irvine, California • Sacramento, California • San Francisco, California + 5 more

Conditions: Relapsed Pediatric Solid Tumors, Refractory Pediatric Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma, Neuroblastoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumor, Desmoid Tumor
Interventions: Magnetic Resonance High Intensity Focused Ultrasound; Device
Lead sponsor: AeRang Kim; Other
Eligibility: Up to 30 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Cincinnati, Ohio

Conditions: ESRD, Fabry Disease, Rare Diseases, Kidney Diseases, End Stage Renal Disease, Genetic Diseases, X-Linked
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Stage III Wilms Tumor
Interventions: laboratory biomarker analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Not listed
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Monrovia, California

Conditions: Klinefelter Syndrome
Interventions: Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution, Placebo injectable saline; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 31 Days to 90 Days · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdoid Tumor of the Kidney, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Carcinoma, Recurrent WHO Grade 2 Glioma, Refractory Adrenal Gland Pheochromocytoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdoid Tumor of the Kidney, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Carcinoma, Refractory WHO Grade 2 Glioma
Interventions: Tipifarnib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 171
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more

Conditions: Pregnancy, Phenylketonuria
Interventions: Metabolic camp; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 11 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2037
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chorioamnionitis
Interventions: Type of glove used for intrapartum vaginal exams; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older · Female only
Enrollment: 507 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions: 17 beta estradiol; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 10 Years to 16 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Chronic Kidney Disease, Endstage Renal Disease
Interventions: Arteriovenous Fistula (AVF), Arteriovenous Graft (AVG); Procedure
Lead sponsor: Columbia University; Other
Eligibility: 65 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Polycystic Ovarian Syndrome (PCOS), Irregular Menstrual Cycles, Androgen Excess
Interventions: doxycycline, Sugar Pill; Drug · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Priapism, Anemia, Sickle Cell
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 5 Years and older · Male only
Enrollment: 1,464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 27
States / cities: Mobile, Alabama • Davis, California • Oakland, California + 16 more

Conditions: Papillomavirus Infections
Interventions: 851B; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 22
States / cities: Colton, California • San Diego, California • Colorado Springs, Colorado + 19 more

Search by objective public record fields.

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Growing Little PEAPODS Study

Natural History of Craniofacial Anomalies and Developmental Growth Variants

ADH1 and ADH2 Disease Monitoring Study (DMS)

Risk Factors, Costs, and Impacts of ED Boarding

The CO2RE® System for Vulvar Lichen Sclerosus

Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer

Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders Study

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors

Kidney Information Network for Disease Research and Education

Studying Biomarkers in Urine Samples From Younger Patients With Wilms Tumor

TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Educational, Social Support, and Nutritional Interventions and Their Cumulative Effect on Pregnancy Outcomes and Quality of Life in Teen and Adult Women With Phenylketonuria

Intrapartum Study of Sterile and Clean Gloves

Estrogen Treatment (Oral vs. Patches) in Turner Syndrome

Comparison of AVF Versus AVG in Elderly Patients Starting Dialysis

Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome

Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.